TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01390246

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 35-min counseling by trained research nurse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Bupropion SR placebo tablet
Study: NCT05805280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ultrasound-guided group
Description: intravascular ultrasound use
Study: NCT01592968

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study: NCT02227888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: S nitrosoglutathione reductase inhibitor
Study: NCT04233411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mycoprotein ingestion
Study: NCT02834624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
Study: NCT05805280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angiography-guided group
Description: angiography-guided use
Study: NCT02687334

Intervention type: DRUG
Intervention: 100% Oxygen
Description: We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
Study: NCT02834624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calfactant
Description: Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
Study: NCT02952235

Intervention type: OTHER
Group type: OTHER
Intervention: SPF50+
Description: Sun protection
Study: NCT04689984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Astaxanthin 6 mg tablet once daily
Study: NCT00357305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01149304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
Study: NCT02640729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelotanserin
Description: once daily, oral, 20-mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, matching tablets
Study: NCT02161718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan + olanzapine (ALKS 3831)
Description: Oral tablet, taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + olanzapine
Description: Oral tablet, taken once daily
Study: NCT03089190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DC7-2
Description: Effects on appetite

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DC7-2 + potato protein isolate
Description: Effects on appetite

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potato protein isolate
Description: Effects on appetite

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive whey protein, not expected to affect appetite.
Study: NCT02015234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: TNX-102 SL 2.8 mg taken daily at bedtime.
Study: NCT01072682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective cytopheretic device (SCD)
Description: The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
Study: NCT03006406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long term GnRH-a (3.75mg)
Description: patient in this group only receive GnRH-a 3.75 for pituitary down-regulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long term GnRH-a (3.75mg)
Description: patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
Study: NCT03887936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62%
Description: Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo gel, apply 2 pumps to upper arm and shoulder
Study: NCT04629664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: Active Comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00358267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Resection of Inferior Turbinates (PRIT)
Description: PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Description: RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
Study: NCT05419206

Intervention type: DIAGNOSTIC_TEST
Intervention: CMV DNA analysis
Description: CMV DNA quantitative viral load levels were studied
Study: NCT02926053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of tumor tissue for T cell production
Description: Surgical removal of \> 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 minutes on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
Study: NCT03634761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competency based model
Description: Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive program
Description: Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive program
Description: Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
Study: NCT02138214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Description: Undergo total thyroidectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Description: Undergo total thyroidectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: entral lymph node dissection (CLND)
Description: Undergo total thyroidectomy with ipsilateral prophylactic CND

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Voice evaluation, interviews, ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Voice evaluation, interviews, ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-life assessment
Description: Voice evaluation, interviews, ancillary studies
Study: NCT03965052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 179
Description: * Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan 0.004 % Ophthalmic Solution
Description: * Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe.
Study: NCT02682654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Scholl's Prototype Ankle Brace
Description: Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Scholl's Prototype Knee Brace
Description: Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
Study: NCT04442737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC
Description: A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D/C/F/TAF FDC
Description: A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF/FTC FDC
Description: TAF/FTC ARV regimen will be administered once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INI Based Regimen
Description: The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
Study: NCT03115424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxenda
Description: Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: RYGB
Description: Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Study: NCT03378596

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline + L-arginine
Description: L-citrulline + L-arginine - sachet dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: L-arginine - sachet dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline - sachet dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (corn starch) - sachet dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (corn starch) - sachet dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (corn starch) - sachet dissolved in water
Study: NCT02569047

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall Technique
Description: It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
Study: NCT01494779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: single subcutaneous dose of 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: single subcutaneous dose of 5mg
Study: NCT01826825

Intervention type: BEHAVIORAL
Intervention: Cognitive Screen
Description: Cognitive Screen

Intervention type: BEHAVIORAL
Intervention: Mini-Cog
Description: Cognitive Screen
Study: NCT00517920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 0.25 mg/kg QD
Study: NCT00142909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lofexidine Placebo
Study: NCT00289796

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV/Hib
Description: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
Study: NCT02669186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Fentanyl
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
Study: NCT04552873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea
Description: the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
Study: NCT04457648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manuka honey 16% eye drops ( Optimel )
Description: 16% manuka honey eye drops, australian FDA approved

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: systane eye drops
Description: systane lubricant eye drops
Study: NCT00871559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN421(SAR153192)
Study: NCT03062891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online CBT for insomnia
Description: See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
Study: NCT04614259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The infraorbital foramen was located at the floor of the orbital rim at about the level of the pupil,The upper lip was folded back and a finger is placed externally at the level of the infraorbital foramen to prevent the needle from the cephalad insertion in the globe of the eye. A 27-gauge needle was bent about 70 degree to ease the insertion through the buccal mucosa over the maxillary process, towards the infraorbital foramen.~After careful aspiration the local anesthetic was injected (injection of 3 ml 0.25% bupivacaine in 1:200.000 adrenaline ,1.5 ml on each side). \[104\] Pressure was needed to be applied for one minute to the area as there is loose adventitious tissue that can lead to swelling and ecchymosis

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: i.v. analgesia
Description: Using inhalational induction with sevoflurane as tolerated , atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted to maintain 30 to 35 mmHg end-tidal carbon dioxide, anesthesia was maintained with 1.5 % isoflurane and atracurium (0.1 mg/kg every 30 minutes) ,all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular .~Blood pressure and heart rate were measured 5 minutes after endotracheal intubation and every 15 minutes till recovery from the anesthesia then every 15 min in the postoperative care unite for 30 minutes
Study: NCT00582582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus doxercalciferol
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel plus placebo
Description: Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
Study: NCT03529630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inverted syringe
Description: Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
Study: NCT02279641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol 300 mg
Study: NCT04411290

Intervention type: PROCEDURE
Intervention: Total thyroidectomy (TT)
Description: Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)